Article Corrected

Tasocitinib. Drugs R D 2010; 10 (4): 271–284

Corrections Made

The drug name has changed and should be referred to as ‘tofacitinib’ throughout the document.

Page 271: In the abstract, the first sentence, which previously read:

“Tasocitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant…”

has now been corrected as follows:

“Tofacitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant…”

Page 271: In the abstract, the second sentence, which previously read:

“Tasocitinib specifically inhibits Janus activated kinase 3 (JAK3), which has…”

has now been corrected as follows:

“Tofacitinib inhibits Janus activated kinase 3 (JAK3), which has…”

Page 272: In the second paragraph of section 1.1.4, the third sentence, which previously read:

“The trial enrolled 249 de novo renal allograft recipients…”

has now been corrected as follows:

“The trial enrolled 61 de novo renal allograft recipients…”

Page 272: In the second paragraph of section 1.1.4, the fifth sentence, which previously read:

“Enrollment of 54 patients was completed…”

has now been corrected as follows:

“Enrollment of 45 patients was completed…”

Page 272: In the third paragraph of section 1.1.5, the first sentence, which previously read:

“…compare the efficacy of tasocitinib with methotrexate…”

has now been corrected as follows:

“…compare the efficacy of two doses of tofacitinib with methotrexate…”

Page 273: In the left column, third paragraph, the first sentence, which previously read:

“…efficacy and safety of tasocitinib in 2500 patients…

has now been corrected as follows:

“…efficacy and safety of tofacitinib in 4000 patients…”

Page 274: In the first paragraph of section 2.2.2, the first sentence, which previously read:

“…were low in the phase II/III ORAL Solo trial…”

has now been corrected as follows:

“…were low in the phase III ORAL Solo trial…”

Page 275: In the left column, second paragraph, the first sentence, which previously read:

“No new safety signals have emerged in the ongoing ORAL Sequel phase II/III 2-year extension study…”

has now been corrected as follows:

“No new safety signals have emerged over 2 years in the ongoing ORAL Sequel phase II/III extension study…”

Page 275: In the right column, second paragraph, the first sentence, which previously read:

“In a 1-year extension study that included patients…”

has now been corrected as follows:

“After 1 year of an extension study that included patients…”

Page 275: In the right column, third paragraph, the first sentence, which previously read:

“…at dosages of 2–20 mg/day,…”

has now been corrected as follows:

“…at doses of 1–10 mg twice daily,…”

Page 277: In the fifth paragraph of section 2.4.1, the first sentence, which previously read:

“Cynomolgus monkeys receiving tasocitinib had a significantly longer…”

has now been corrected as follows:

“Cynomolgus monkeys receiving tofacitinib following bilateral nephrectomy and allogeneic renal transplant had a significantly longer…”

Page 278: In the right column, lines 1 and 2, which previously read:

“…twice daily groups at 6 months, compared with the placebo group.”

has now been corrected as follows:

“…twice daily groups at 3 months, compared with the placebo group.”

Page 281: In the left column, second paragraph, which previously read:

“…significantly improved pain and physical function at 6 weeks…”

has now been corrected as follows:

“…significantly improved ACR response rates at 6 weeks…”

Page 281: In the right column, the second paragraph starting with “One-year efficacy data…” should be deleted entirely.

Page 281: In the right column, third paragraph, the first sentence, which previously read:

“Tasocitinib, at dosages of 2–20 mg/day, was effective…”

has now been corrected as follows:

“Tofacitinib, at doses of 1–10 mg twice daily, was effective…”

Note

All online versions of this article have been updated to reflect these corrections.